Clinical Response Predictive Model for Omalizumab in Moderate-to-Severe Asthma Patients

Table 1

Baseline characteristics of participants recruited in this study.

Characteristics	N = 108	Responders	Nonresponders	t/Z/	value
Age at visit 1 (years old)	39.86 ± 14.59	40.27 ± 14.58	35.28 ± 13.58	−1.326	0.188
Male, n (%)	61 (56.48%)	47 (63.51%)	8 (53.33%)	1.352	0.245
Weight (kg)	68.34 ± 10.28	69.29 ± 10.44	64.22 ± 9.19	1.900	0.060
Course of asthma (years)	5 (2–10)	5 (2–10)	8.5 (5–14)	−1.382	0.167
Family history of allergic diseases, n (%)	58 (53.7%)	47 (92.2%)	4 (25.67%)	8.168	0.004
Ocs, n (%)	19 (17.6%)	15 (88.2%)	2 (13.33%)		0.731
Concomitant asthma medications, n (%)	46 (42.6%)	29 (74.4%)	10 (66.67%)	2.166	0.141
No. of protocol-defined exacerbations during the past year				7.078	0.008
<2 times	54 (50.00%)	33 (44.59%)	12 (80.00%)
≥2 times	54 (50.00%)	41 (55.41%)	3 (20.00%)
HBP, n (%)	18 (16.7%)	12 (16.22%)	1 (6.67%)		0.456
DM, n (%)	5 (4.6%)	4 (5.41%)	0 (0.00%)		1.000
Rhinitis, n (%)	101 (93.5%)	71 (95.95%)	13 (86.67%)		0.308
Rash, n (%)	37 (34.3%)	23 (31.08%)	9 (60.00%)	4.081	0.043
Omalizumab dose (mg)				2.251	0.530
150	22 (20.4%)	11 (14.86%)	4 (26.67%)
300	37 (34.3%)	31 (41.89%)	3 (20.00%)
450	29 (26.9%)	21 (28.38%)	4 (26.67%)
600	20 (18.5%)	11 (14.86%)	4 (26.67%)
EOS	0.24 (0.10–0.43)	0.24 (0.10–0.44)	0.24 (0.08–0.31)		0.385
IgE	260.98 (116.74–449.58)	270.76 (140.47–432.64)	250 (65.99–398.01)		0.517

HBP: high blood pressure; DM: diabetes mellitus. The bold values indicate that the differences observed are statistically significant ().